Business Wire

Grassi & Co. Introduces COMPASS-Regulatory and Compliance Advisers and Welcomes Gary Swiman and Larry Wagner


Grassi & Co. continues to invest in the Compliance and Regulatory Consulting space and is proud to announce the affiliation of COMPASS-Regulatory and Compliance Advisers—led by Gary Swiman as its President, and Larry Wagner, its Managing Director. The practice will be based out of Grassi & Co.’s Manhattan office.

This Smart News Release features multimedia. View the full release here:

Gary Swiman, President, COMPASS Regulatory and Compliance Advisers (Photo: Business Wire)

Gary Swiman, President, COMPASS Regulatory and Compliance Advisers (Photo: Business Wire)

Prior to joining Grassi & Co., Gary has held CCO and senior regulatory positions at major broker-dealers as well as large international asset managers. Gary also served as a partner and head of regulatory and compliance services at two top 30 accounting firms. Gary has more than 25 years of experience implementing compliance programs for hedge funds, private equity funds, registered investment advisers, investment banks and broker-dealers. He works with financial industry clients to navigate evolving regulatory requirements, and works closely with clients, law firms and regulators on high level enforcement matters. A Certified Public Accountant, Gary graduated Cum Laude with a Juris Doctorate from Fordham Law School. Gary also holds CAMS, CFF and CFE licenses.

Larry Wagner is a seasoned executive with 30+ years of achievement in small to large-sized businesses, capital markets, investment banking, hedge funds, private equity and alternative asset management industries. As an experienced CFO, Larry gained a unique perspective of finance having spent significant time in both private and multi-national public entities.

Larry was the CFO of Nomura Holdings America (Investment Bank, Private Equity and Asset Management Companies) and the CFO of ING Financial Services LLC and earned his B.S. in Accounting from the State University of New York at Albany. Larry holds a CPA and CAMS license.

“As regulatory and compliance focus on the financial services industry continues to intensify, we are excited to bring an established compliance and regulatory practice to Grassi & Co. and be able to offer these value added services to our clients,” said Louis C. Grassi, Managing Partner and CEO of Grassi & Co. “Gary and Larry’s approach is unique in providing practical subject matter expertise tailored to each client’s industry and business model. This approach results in meeting the client’s regulatory objectives at a fair price without disrupting the client’s business initiatives.”

Both professionals have been widely quoted and looked upon as experts in such publications as the Wall Street Journal and Financial Times.

Among other financial institutions the team serves broker dealers, banks, investment advisers and investment companies. The team advises financial institutions on regulatory and compliance matters, implementing compliance best practices, compliance program development, policy and procedure revision, forensic testing and monitoring, on-site training, governance processes and reporting, investment company regulations, banking regulations, Broker-dealer and Investment Adviser registrations, anti-money laundering policies, procedures and enforcement remediation and enforcement legal support. The team has successfully negotiated settlements and changed the direction of regulatory examinations conducted by the SEC and FINRA, and other Federal and State regulators.

About Grassi & Co.: Grassi & Co., the 70th largest firm in the U.S., is a premier professional service organization specializing in accounting, auditing, tax, technology, and business consulting services. Grassi & Co. has offices in Manhattan, Long Island and Rockland County, NY as well as internationally through its association with Moore Stephens International. Grassi & Co. specializes in professional services for the Not-for-Profit, Construction, Architecture & Engineering, Financial Services, Life Sciences, Manufacturing & Distribution, Retail, Technology, Media & Telecommunication, Transportation, Energy & Natural Resources, and Healthcare industries, among others.

Contact information

Grassi & Co.
J. Maizel, 516-918-5927

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Seoul Semiconductor’s SunLike Series LEDs Win Product of the Year Award from Elektronik Magazine23.3.2018 18:28Pressemelding

Seoul Semiconductor, a global innovator of LED products and technology, announced on March 23rd that its SunLike Series natural spectrum LED product won the Gold Award at the Elektronik Product of the Year 2018 Awards, hosted by Elektronik (, a leading German electronics publication. This press release features multimedia. View the full release here: Product of the Year Award from Elektronik Magazine (SunLike) (Photo: Business Wire) As a publication specializing in electrical and electronic components, “Elektronik” is a prestigious magazine with an illustrious history and the largest number of subscribers in Germany. Over the past 20 years, they have conducted annual surveys among their subscribers to find the “most creative and innovative products.” Based on these survey results, Elektronik selects the top product that with the most impact in its corresponding field, and confers the awards accordingl

Elliott Welcomes Imminent Bezeq Board Overhaul and New Era for Strong Independent Governance23.3.2018 16:05Pressemelding

Elliott Advisors (UK) Limited (“Elliott”), which advises funds which collectively hold a significant economic interest in Bezeq The Israeli Telecommunication Corporation Ltd. (“Bezeq” or the “Company”), welcomes the proposed governance reforms announced by Bezeq last night. In its initial letter to Bezeq Interim Chairman David Granot, dated January 16, 2018, Elliott outlined the urgent need to address the Company’s serious corporate governance issues, and called for changes at the Board level that result in “the right mixture of expertise, independence and integrity for the future.” Elliott stated then, and reiterates now, its belief that “there is significant value to be unlocked if the right steps are taken to improve its corporate governance.” Bezeq has strong business fundamentals, an exemplary workforce, and great potential. Following yesterday’s announcement, Elliott highlights the changes that have occurred since January 16th. Taken together, these amount to a revolution in the

Clovis Oncology Initiates Early Access Program for Rucaparib as Treatment and as Maintenance Therapy in Recurrent Ovarian Cancer in Europe23.3.2018 12:52Pressemelding

Clovis Oncology, Inc. (NASDAQ:CLVS) today announced the initiation of an early access program in Europe for rucaparib for treatment and as maintenance therapy in recurrent ovarian cancer. The program will be overseen and implemented by Caligor Coghlan, which specializes in early access to medicines. The program, to be known as the Rucaparib Access Program (RAP), will enable participation from certain countries in Europe, where permitted by applicable rules, procedures and regulatory authorities. The RAP protocol allows for rucaparib treatment of an individual patient with third-line or greater BRCA mutant epithelial, fallopian tube, or primary peritoneal ovarian cancer who has platinum-sensitive disease and is unable to tolerate further platinum-based chemotherapy or has platinum-resistant disease and needs treatment with single agent rucaparib. The RAP protocol will also provide access to rucaparib for maintenance therapy of an individual patient with recurrent epithelial ovarian, fal

CHMP Grants Positive Opinion for Clovis Oncology’s Rubraca® (rucaparib) Tablets23.3.2018 12:50Pressemelding

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Union’s (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a conditional marketing authorization for Rubraca as monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy. The European Marketing Authorization application for the treatment indication was based on objective response rate and duration of response results from two multicenter, single-arm, open-label clinical trials, Study 10 and ARIEL2, in women with advanced BRCA mutant ovarian cancer who had progressed after two or more prior chemotherapies. “The recommendation

Janssen Announces Positive CHMP Opinion for JULUCATM▼ (dolutegravir/rilpivirine)23.3.2018 12:46Pressemelding

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a Positive Opinion recommending marketing authorisation for JULUCA™ (dolutegravir 50mg [ViiV Healthcare UK Ltd]/rilpivirine 25mg [Janssen Sciences Ireland UC]). Dolutegravir/rilpivirine is a single-pill, two-drug regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 c/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor (NNRTI) or integrase strand transfer inhibitor (INSTI).1 “We are delighted to be one step closer to bringing JULUCA™ to people living with HIV in Europe,” said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, LLC. “Building on our 25-year c

Aitheon Executives Educate World Leaders on Benefits, Challenges of AI at the Annual World Government Summit in Dubai23.3.2018 12:00Pressemelding

Aitheon, makers of the world’s first blockchain-powered platform to solve real problems by integrating AI, robotics, IoT, human specialists and cryptocurrency, announced today that executives from the company held a series of high-level briefings with world leaders at the Annual World Government Summit in Dubai. Briefings covered the benefits and challenges of AI, and revolutionary new solutions to world challenges made possible by transformative new technologies. (Read the full release at This press release features multimedia. View the full release here: Aitheon founder and CEO, Andrew Archer, and Chief Strategy Officer, Ryan Burleson, were invited to brief leaders at the Summit by Cyrus Hodes, Co-founder and Director of the AI Initiative, an undertaking of the Future Society at Harvard University’s Kennedy School. Archer and Burleson addressed a variety of AI-related topics, including the impact of AI on